您的位置: 首页 » 法律资料网 » 法律法规 »

企业内部控制应用指引第8号——资产管理

时间:2024-07-11 18:30:55 来源: 法律资料网 作者:法律资料网 阅读:9817
下载地址: 点击此处下载

企业内部控制应用指引第8号——资产管理

财政部


企业内部控制应用指引第8号——资产管理



第一章总则

第一条为了提高资产使用效能,保证资产安全,根据有关法律法规和《企业内部控制基本规范》,制定本指引。

第二条本指引所称资产,是指企业拥有或控制的存货、固定资产和无形资产。

第三条企业资产管理至少应当关注下列风险:(一)存货积压或短缺,可能导致流动资金占用过量、存货价值贬损或生产中断。

(二)固定资产更新改造不够、使用效能低下、维护不当、产能过剩,可能导致企业缺乏竞争力、资产价值贬损、安全事故频发或资源浪费。

(三)无形资产缺乏核心技术、权属不清、技术落后、存在重大技术安全隐患,可能导致企业法律纠纷、缺乏可持续发展能力。

第四条企业应当加强各项资产管理,全面梳理资产管理流程,及时发现资产管理中的薄弱环节,切实采取有效措施加以改进,并关注资产减值迹象,合理确认资产减值损失,不断提高企业资产管理水平。

企业应当重视和加强各项资产的投保工作,采用招标等方式确定保险人,降低资产损失风险,防范资产投保舞弊。

第二章存货

第五条企业应当采用先进的存货管理技术和方法,规范存货管理流程,明确存货取得、验收入库、原料加工、仓储保管、领用发出、盘点处置等环节的管理要求,充分利用信息系统,强化会计、出入库等相关记录,确保存货管理全过程的风险得到有效控制。

第六条企业应当建立存货管理岗位责任制,明确内部相关部门和岗位的职责权限,切实做到不相容岗位相互分离、制约和监督。

企业内部除存货管理、监督部门及仓储人员外,其他部门和人员接触存货,应当经过相关部门特别授权。

第七条企业应当重视存货验收工作,规范存货验收程序和方法,对入库存货的数量、质量、技术规格等方面进行查验,验收无误方可入库。

外购存货的验收,应当重点关注合同、发票等原始单据与存货的数量、质量、规格等核对一致。涉及技术含量较高的货物,必要时可委托具有检验资质的机构或聘请外部专家协助验收。

自制存货的验收,应当重点关注产品质量,通过检验合格的半成品、产成品才能办理入库手续,不合格品应及时查明原因、落实责任、报告处理。

其他方式取得存货的验收,应当重点关注存货来源、质量状况、实际价值是否符合有关合同或协议的约定。

第八条企业应当建立存货保管制度,定期对存货进行检查,重点关注下列事项:(一)存货在不同仓库之间流动时应当办理出入库手续。

(二)应当按仓储物资所要求的储存条件贮存,并健全防火、防洪、防盗、防潮、防病虫害和防变质等管理规范。

(三)加强生产现场的材料、周转材料、半成品等物资的管理,防止浪费、被盗和流失。

(四)对代管、代销、暂存、受托加工的存货,应单独存放和记录,避免与本单位存货混淆。

(五)结合企业实际情况,加强存货的保险投保,保证存货安全,合理降低存货意外损失风险。

第九条企业应当明确存货发出和领用的审批权限,大批存货、贵重商品或危险品的发出应当实行特别授权。仓储部门应当根据经审批的销售(出库)通知单发出货物。

第十条企业仓储部门应当详细记录存货入库、出库及库存情况,做到存货记录与实际库存相符,并定期与财会部门、存货管理部门进行核对。

第十一条企业应当根据各种存货采购间隔期和当前库存,综合考虑企业生产经营计划、市场供求等因素,充分利用信息系统,合理确定存货采购日期和数量,确保存货处于最佳库存状态。

第十二条企业应当建立存货盘点清查制度,结合本企业实际情况确定盘点周期、盘点流程等相关内容,核查存货数量,及时发现存货减值迹象。企业至少应当于每年年度终了开展全面盘点清查,盘点清查结果应当形成书面报告。

盘点清查中发现的存货盘盈、盘亏、毁损、闲置以及需要报废的存货,应当查明原因、落实并追究责任,按照规定权限批准后处置。

第三章固定资产

第十三条企业应当加强房屋建筑物、机器设备等各类固定资产的管理,重视固定资产维护和更新改造,不断提升固定资产的使用效能,积极促进固定资产处于良好运行状态。

第十四条企业应当制定固定资产目录,对每项固定资产进行编号,按照单项资产建立固定资产卡片,详细记录各项固定资产的来源、验收、使用地点、责任单位和责任人、运转、维修、改造、折旧、盘点等相关内容。

企业应当严格执行固定资产日常维修和大修理计划,定期对固定资产进行维护保养,切实消除安全隐患。

企业应当强化对生产线等关键设备运转的监控,严格操作流程,实行岗前培训和岗位许可制度,确保设备安全运转。

第十五条企业应当根据发展战略,充分利用国家有关自主创新政策,加大技改投入,不断促进固定资产技术升级,淘汰落后设备,切实做到保持本企业固定资产技术的先进性和企业发展的可持续性。

第十六条企业应当严格执行固定资产投保政策,对应投保的固定资产项目按规定程序进行审批,及时办理投保手续。

第十七条企业应当规范固定资产抵押管理,确定固定资产抵押程序和审批权限等。

企业将固定资产用作抵押的,应由相关部门提出申请,经企业授权部门或人员批准后,由资产管理部门办理抵押手续。

企业应当加强对接收的抵押资产的管理,编制专门的资产目录,合理评估抵押资产的价值。

第十八条企业应当建立固定资产清查制度,至少每年进行全面清查。对固定资产清查中发现的问题,应当查明原因,追究责任,妥善处理。

企业应当加强固定资产处置的控制,关注固定资产处置中的关联交易和处置定价,防范资产流失。

第四章无形资产

第十九条企业应当加强对品牌、商标、专利、专有技术、土地使用权等无形资产的管理,分类制定无形资产管理办法,落实无形资产管理责任制,促进无形资产有效利用,充分发挥无形资产对提升企业核心竞争力的作用。

第二十条企业应当全面梳理外购、自行开发以及其他方式取得的各类无形资产的权属关系,加强无形资产权益保护,防范侵权行为和法律风险。无形资产具有保密性质的,应当采取严格保密措施,严防泄露商业秘密。

企业购入或者以支付土地出让金等方式取得的土地使用权,应当取得土地使用权有效证明文件。

第二十一条企业应当定期对专利、专有技术等无形资产的先进性进行评估,淘汰落后技术,加大研发投入,促进技术更新换代,不断提升自主创新能力,努力做到核心技术处于同行业领先水平。

第二十二条企业应当重视品牌建设,加强商誉管理,通过提供高质量产品和优质服务等多种方式,不断打造和培育主业品牌,切实维护和提升企业品牌的社会认可度。


Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.


甲型H1N1流感病例密切接触者判定与管理方案(试行)

卫生部


甲型H1N1流感病例密切接触者判定与管理方案(试行)


  为科学地判定甲型H1N1流感病例的密切接触者,对其进行追踪和医学观察,依法、科学、及时、有序地采取有效防控措施,防止疫情的进一步传播、扩散,特制订本指南。

  一、密切接触者的判定

  甲型H1N1流感病例包括疑似病例和确诊病例,以下简称甲型H1N1流感病例。

  根据世界卫生组织和美国疾病预防控制中心目前的技术指南,甲型H1N1流感的传染期是自病人出现症状前1天至发病后7天,或至病例症状消失后24小时(以两者之间较长者为准)。甲型H1N1流感的潜伏期1-7天。

  密切接触者是指在未采取有效防护情况下接触传染期甲型H1N1流感病例的人群,具体包括:诊断、治疗或护理、探视甲型H1N1流感病例的人员;与病例共同生活或有过近距离接触的人员;或直接接触过病例的呼吸道分泌物、体液;或可能暴露于病例污染的环境或物体的人员等。

  在判定密切接触者,分析其感染发病的可能性时,要综合考虑与病例接触时,病例是否处于传染期、病例的临床表现、与病例的接触方式、接触时所采取的防护措施,以及暴露于病例污染的环境和物体的程度等因素,进行综合判断,以采取有针对性的防控措施。

  二、密切接触者的调查及追踪

  (一)各地卫生部门应在当地政府的领导下,与有关部门密切配合,采取一切必要措施追查病人的所有密切接触者;涉及跨区域的密切接触者,可通知有关省份协助追查。

  (二)所在地疾病预防控制机构负责对密切接触者进行登记和调查。

  (三)对涉及外籍密切接触者的有关情况,地方卫生行政部门应立即向当地外事部门报告并向卫生部通报。

  三、密切接触者管理

  加强甲型H1N1流感病例密切接触者的管理工作,有利于延迟甲型H1N1流感的传播蔓延。在该病的流行初期、流行高峰或流行后不同阶段,密切接触者的管理工作要求将适时作出相应调整。

  (一)各地卫生行政部门负责组织实施密切接触者的医学观察工作。可根据实际情况,对密切接触者进行指定场所集中医学观察或居家医学观察。

  (二)医学观察期间是指密切接触者与病例或污染物品等最后一次接触之日起顺延至第7天结束。

  (三)在进行医学观察前,要向密切接触者说明医学观察的依据、期限及有关注意事项;告知负责医学观察的医疗卫生机构及相关人员的联系方式;做好科普知识宣传,包括甲型H1N1流感的临床特点、传播途径、预防方法等信息。

  (四)居家医学观察的密切接触者及同居所的人员不得外出,集中观察的密切接触者应保障分室居住。

  (五)医学观察期间应采取以下措施:

  1.由当地卫生行政部门指定医疗卫生机构每日对密切接触者的健康状况进行访视(早晚两次测试体温),详细记录密切接触者的健康状况。对年老体弱者及婴幼儿还应注意了解有无其他病症。

  2. 集中医学观察场所应每日向当地卫生行政部门报告密切接触者医学观察情况。集中医学观察场所应配备必要的消毒设施、消毒剂和个人防护用品,认真做好本场所的清洁与消毒工作。

  3. 实施医学观察的工作人员应做好基本的个人防护。

  (六)医学观察期间,密切接触者如出现急性发热或呼吸道症状,应立即送定点医疗机构进行隔离治疗、采样和检测,并对与其有密切接触的全部人员进行医学观察。如密切接触者排除甲型H1N1流感,与其有密切接触的全部人员解除医学观察。

  (七)医学观察期满,如密切接触者无异常情况,应及时解除医学观察,并由负责医学观察的医疗卫生机构出具书面健康证明。